Impact Of Sacral Neuromodulation On Urine Markers For Interstitial Cystitis (IC)
Urine will be collected and sent to the University of Maryland. Urines will be analyzed for urine markers.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Impact Of Sacral Neuromodulation On Urine Markers For IC|
- The purpose of this study is measure urine biomarkers levels in patients with interstitial cystitis who have elected to undergo sacral nerve stimulation as a treatment modality for their disease. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Urines were collected and sent for urine marker analysis.
|Study Start Date:||February 2004|
|Study Completion Date:||December 2007|
|Primary Completion Date:||December 2006 (Final data collection date for primary outcome measure)|
One arm study. Urine collection.
Urine will be collected and flash frozen in liquid nitrogen then placed in a -70 C freezer. All urine will be collected and stored until the final follow-up is complete. The urine samples will then be sent as a single batch to the Department of Infectious Disease, University of Maryland. Urines will be assayed in a blinded fashion and a written report of the levels of each of the 3 urine markers will be sent to Beaumont Hospital. Change in urine marker levels will be analyzed and correlated with change in symptom scores.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00704457
|United States, Michigan|
|Beaumont Hospital - Royal Oak|
|Royal Oak, Michigan, United States, 48073|
|Principal Investigator:||Kenneth Peters, MD||William Beaumont Hospitals|